PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POST-MENOPAUSAL OSTEOPOROSIS

Author(s)

Penning-van Beest FJA1, Goettsch WG2, Erkens JA2, Herings RMC2, 1 PHARMO Institute, Utrecht, Utrecht, Netherlands; 2 PHARMO Institute, Utrecht, Netherlands

OBJECTIVES: The aim of this study was to compare the persistence of use of daily and weekly administered bisphosphonates. METHODS: Data were obtained from the PHARMO database, which includes linked drug-dispensing records and hospital records of more than one million subjects in defined areas in the Netherlands. New female users of alendronate, etidronate or risedronate aged 55 years and older in the period January, 2000 - September, 2003, were included in the study cohort. One-year persistence of treatment was determined by using episodes of bisphosphonate treatment based on the method of Catalan. The effect of the dosing regimen and other determinants including age, co-medication and fractures, on persistence was assessed. RESULTS: The study cohort included 2124 new users of bisphosphonates. Overall, one-year persistence of bisphosphonates was low; only 911 (43%) users were persistent. Etidronate users were less persistent (30%) than alendronate and risedronate users (46% and 42%, respectively). Among alendronate users, patients on the weekly regimen were more persistent (52%) than those on the daily regimen (35%). A multivariate analysis including age, co-medication and fractures, showed that patients using alendronate weekly were 2.26 times more likely to be persistent (95%CI 1.66 - 3.09) compared to patients using alendronate daily. CONCLUSIONS: Our results indicate that persistence of bisphosphonate use is higher with a less frequent dosing regimen. The improved persistence of the weekly administered alendronate may theoretically be explained by a reduced frequency to experience drug-related acute adverse effects. However, persistence for both regimens can be considered to be suboptimal and leaves room for improvement.

Conference/Value in Health Info

2004-10, ISPOR Europe 2004, Hamburg, Germany

Value in Health, Vol. 7, No. 6 (November/December 2004)

Code

POS8

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×